WO1994026903A3 - Human influenza virus peptides binding hla-i molecule - Google Patents

Human influenza virus peptides binding hla-i molecule Download PDF

Info

Publication number
WO1994026903A3
WO1994026903A3 PCT/NL1994/000114 NL9400114W WO9426903A3 WO 1994026903 A3 WO1994026903 A3 WO 1994026903A3 NL 9400114 W NL9400114 W NL 9400114W WO 9426903 A3 WO9426903 A3 WO 9426903A3
Authority
WO
WIPO (PCT)
Prior art keywords
human influenza
influenza virus
molecule
peptides binding
virus peptides
Prior art date
Application number
PCT/NL1994/000114
Other languages
French (fr)
Other versions
WO1994026903A2 (en
Inventor
Cornelis Joseph Maria Melief
Wybe Martin Kast
Original Assignee
Univ Leiden
Seed Capital Investments
Cornelis Joseph Maria Melief
Wybe Martin Kast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Seed Capital Investments, Cornelis Joseph Maria Melief, Wybe Martin Kast filed Critical Univ Leiden
Priority to AU68585/94A priority Critical patent/AU6858594A/en
Publication of WO1994026903A2 publication Critical patent/WO1994026903A2/en
Publication of WO1994026903A3 publication Critical patent/WO1994026903A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A peptide comprising an amino acid sequence derived from a human influenza virus protein, such as the human influenza M protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of a human influenza virus-related disease, or in a diagnostic test or assay.
PCT/NL1994/000114 1993-05-18 1994-05-18 Human influenza virus peptides binding hla-i molecule WO1994026903A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU68585/94A AU6858594A (en) 1993-05-18 1994-05-18 Human influenza virus peptides binding hla-t molecule

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93201429 1993-05-18
EP93201429.3 1993-05-18

Publications (2)

Publication Number Publication Date
WO1994026903A2 WO1994026903A2 (en) 1994-11-24
WO1994026903A3 true WO1994026903A3 (en) 1995-06-01

Family

ID=8213836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1994/000114 WO1994026903A2 (en) 1993-05-18 1994-05-18 Human influenza virus peptides binding hla-i molecule

Country Status (4)

Country Link
AU (1) AU6858594A (en)
IL (1) IL109664A0 (en)
WO (1) WO1994026903A2 (en)
ZA (1) ZA943438B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE466869T1 (en) * 1993-03-05 2010-05-15 Epimmune Inc METHOD FOR PRODUCING IMMUNOGENIC HLA-A2.1-BINDING PEPTIDES
WO1995004817A1 (en) * 1993-08-06 1995-02-16 Cytel Corporation Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6015884A (en) 1996-03-28 2000-01-18 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6268411B1 (en) * 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
ATE552846T1 (en) 2005-12-06 2012-04-15 Yeda Res & Dev IMPROVED FLU VACCINE
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
EP1843158A1 (en) * 2006-04-05 2007-10-10 Micronas Holding GmbH Pathogen detection system
CA2657849A1 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
AU2009221419B2 (en) 2008-02-01 2013-09-26 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008852A1 (en) * 1987-05-14 1988-11-17 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008852A1 (en) * 1987-05-14 1988-11-17 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FALK, K. ET AL.: "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules", NATURE., vol. 351, 23 May 1991 (1991-05-23), LONDON GB, pages 290 - 296 *
MORRISON, J. ET AL.: "Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 22, no. 4, 1992, WEINHEIM, BRD, pages 903 - 907 *
NIJMAN H. W. ET AL.: "Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, no. 6, June 1993 (1993-06-01), pages 1215 - 1219 *
SAUMA, S.Y. ET AL.: "Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the Influenza A virus Matrix Protein", HUMAN IMMUNOLOGY, vol. 37, no. 4, August 1993 (1993-08-01), pages 252 - 258 *

Also Published As

Publication number Publication date
AU6858594A (en) 1994-12-12
IL109664A0 (en) 1994-08-26
ZA943438B (en) 1995-01-20
WO1994026903A2 (en) 1994-11-24

Similar Documents

Publication Publication Date Title
IL105554A0 (en) Peptides of human papilloma virus for use in human t cell response inducing compositions
EP2368907A3 (en) Anti-Abeta antibodies and their use
WO1994026903A3 (en) Human influenza virus peptides binding hla-i molecule
DK0643726T3 (en) Human p53 protein peptides for use in compositions that induce human T cell response and human p53 protein
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
EP1918298A3 (en) Peptide
CA2181150A1 (en) Biologically Active Peptides from Functional Domains of Bactericidal/Permeability-Increasing Protein and Uses Thereof
WO1995011975A3 (en) Retroviral superantigens, superantigen peptides, and methods of use
EP1071443A4 (en) Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein bind to mhc class i and mhc class ii molecules, and uses thereof
WO2001027136A3 (en) Peptides which stimulate the immune response and tissue regeneration
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2000049038A3 (en) Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
SE9800504D0 (en) Novel peptide / protein, diagnostic reagent and kit for detection of rickettsiosis
NZ335136A (en) Isolated peptides which complex with hla-cw*16 molecules, and uses thereof
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
WO1998023752A3 (en) Papilloma viruses, agents for detecting the same and for treating diseases caused by such viruses
CA2163212A1 (en) Therapeutic compounds
EP2143730A3 (en) Modified peptides and their use for the treatment of autoimmune diseases
WO1998042847A3 (en) Papilloma virus main capsid protein and the use thereof in diagnosis, therapy and vaccination
HUP0104254A2 (en) Regulatory/unfolding peptides of ezrin
WO1999009177A3 (en) Papilloma virus, agents for the detection thereof and for the therapy of the diseases caused by said virus
AU4712993A (en) New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
CA2112701A1 (en) Proteins s polypeptides and uses thereof
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA